Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?

Area of Science:

• Oncology
• Neuro-oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is the most frequently mutated oncogene in glioblastoma (GBM).
• Targeting EGFR is a key strategy in GBM therapy, with numerous inhibitors investigated in clinical trials.
• Current anti-EGFR therapies in GBM have yielded unsatisfactory clinical outcomes.

Purpose of the Study:

• To review recent advances in EGFR-targeted therapy for glioblastoma.
• To elucidate the reasons behind the limited efficacy of EGFR inhibitors in GBM.
• To propose promising strategies for overcoming therapeutic resistance in GBM.

Main Methods:

• Comprehensive literature review of preclinical studies and clinical trials on EGFR-targeted therapy in GBM.
• Analysis of factors contributing to treatment failure, including blood-brain barrier (BBB) penetration and drug resistance.
• Discussion of potential therapeutic strategies based on current research findings.

Main Results:

• Limited BBB permeability, acquired drug resistance, and adaptive pathway signaling impede the effectiveness of EGFR inhibitors.
• Preclinical and clinical data highlight the challenges associated with monotherapy targeting the EGFR pathway in GBM.
• The review identifies key obstacles that need to be addressed for successful EGFR-targeted treatment in GBM.

Conclusions:

• Overcoming drug resistance in GBM requires innovative therapeutic approaches beyond simple EGFR inhibition.
• Strategies such as enhancing drug BBB penetration, employing multi-target combination therapies, and developing peptidomimetic drugs show potential.
• Precision medicine frameworks are crucial for developing effective, personalized treatments for glioblastoma patients.